The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Association between BMI and prognosis in NSCLC patients treated with TKIs
Roberto Borea, MD, The Ohio State University, Columbus, OH, discusses findings from a pilot study investigating the association between body mass index (BMI) and outcomes in patients with non-small cell lung cancer (NSCLC). Patients with a higher BMI treated with tyrosine kinase inhibitors were found to have a much better prognosis than those with a lower BMI, which was also found for patients treated with immune checkpoint inhibitors but with a less significant difference. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
